Second line therapy in malignant pleural mesothelioma: A systematic review

Lung Cancer

Volumn 89, Issue 3, 2015, Pages 223-231

  Buikhuisen, Wieneke A ^a   Hiddinga, Birgitta I ^b   Baas, Paul ^a   van Meerbeeck, Jan P ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Biological; Chemotherapy; Mesothelioma; Meta analysis; Outcome; Second line; Targeted treatment; Treatment

Indexed keywords

6 METHOXY 2 METHYL 3 (3,4,5 TRIMETHOXYBENZOYL)BENZOFURAN 7 YL PHOSPHATE DISODIUM; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL PRODUCT; BORTEZOMIB; CEDIRANIB; CYCLOPHOSPHAMIDE; ERLOTINIB; EVEROLIMUS; GEMCITABINE; IMATINIB; IMMUNOMODULATING AGENT; NAVELBINE; NGR HTNF; PEMBROLIZUMAB; PEMETREXED; PENTOSTATIN; PICOPLATIN; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; SORAFENIB; SS1P; SUNITINIB; THALIDOMIDE; TICILIMUMAB; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VATALANIB; VORINOSTAT;

ABSENCE OF SIDE EFFECTS; BACKACHE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LUNG TOXICITY; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NEUROTOXICITY; NEUTROPENIA; PERIPHERAL EDEMA; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PLEURAL PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOCYTOPENIA; TOXIC HEPATITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PLEURAL NEOPLASMS; RETREATMENT;

COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; RETREATMENT; TREATMENT OUTCOME;

EID: 84938742913     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.06.018     Document Type: Review

References (61)

1. Anonymous The Helsinki Consensus report on diagnosis and attribution. Scand. J. Work Environ. Health 1997, 23:311-318.
2. Wagner J.C., Sleggs C.A., Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med. 1960, 17:260-271.
3. Carbone M., Ly B.H., Dodson R.F., et al. Malignant mesothelioma: facts, myths, and hypotheses. J. Cell. Physiol. 2012, 227:44-58.
4. Stayner L., Welch L.S., Lemen R. The worldwide pandemic of asbestos-related diseases. Annu. Rev. Public Health 2013, 34:205-216.
5. Muers M.F., Stephens R.J., Fisher P., et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371:1685-1694.
6. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003, 21:2636-2644.
7. van Meerbeeck J.P., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 2005, 23:6881-6889.
8. Woods B., Paracha N., Scott D.A., et al. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer 2012, 75:261-267.
9. Damhuis R.A., Schroten C., Burgers J.A. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur. Respir. J. 2012, 40:185-189.
10. Scherpereel A., Astoul P., Baas P., et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur. Respir. J. 2010, 35:479-495.
11. Gehan E.A. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chronic Dis. 1961, 13:346-353.
12. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
13. Manegold C., Symanowski J., Gatzemeier U., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann. Oncol. 2005, 16:923-927.
14. Taylor P., Castagneto B., Dark G., et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J. Thorac. Oncol. 2008, 3:764-771.
15. Janne P.A., Wozniak A.J., Belani C.P., et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J. Thorac. Oncol. 2006, 1:506-512.
16. Ellis P., Davies A.M., Evans W.K., et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J. Thorac. Oncol. 2006, 1:591-601.
17. Sorensen J.B., Sundstrom S., Perell K., et al. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J. Thorac. Oncol. 2007, 2:147-152.
18. Jassem J., Ramlau R., Santoro A., et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J. Clin. Oncol. 2008, 26:1698-1704.
19. Stebbing J., Powles T., McPherson K., et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009, 63:94-97.
20. Giaccone G., O'Brien M.E., Byrne M.J., et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur. J. Cancer 2002, 38(Suppl. 8):S19-S24.
21. Tourkantonis I., Makrilia N., Ralli M., et al. Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study. Am. J. Clin. Oncol. 2011, 34:38-42.
22. Porta C., Zimatore M., Bonomi L., et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 2005, 48:429-434.
23. Fizazi K., Doubre H., Le Chevalier T., et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J. Clin. Oncol. 2003, 21:349-354.
24. Vandermeers F., Hubert P., Delvenne P., et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin. Cancer Res. 2009, 15:2818-2828.
25. Scherpereel A., Berghmans T., Lafitte J.J., et al. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur. Respir. J. 2011, 37:129-135.
26. Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 2013, 34:1413-1419.
27. Li W., You L., Cooper J., et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010, 140:477-490.
28. Garland L.L., Ou S., Moon J., Mack P., Testa J., Tsao N., et al. SWOG 0722: a phase II study of mTOR inhibitor everolimus (RAD 001) in malignant pleural mesothelioma (MPM). ASCO Annual Meeting 2012, (abstract #7083).
29. Wagner A.J., Bendell J.C., Dolly S. A first in human phase 1 study to evaluate GDC-0980, an oral P13K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J. Clin. Oncol. 2011, 29. supplement (abstract #3020).
30. Shapiro I.M., Kolev V.N., Vidal C.M., et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci. Transl. Med. 2014, 6. 237ra268.
31. Bott M., Brevet M., Taylor B.S., et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 2011, 43:668-672.
32. Ventii K.H., Devi N.S., Friedrich K.L., et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008, 68:6953-6962.
33. Krug L.M., Kindler H.L., Calvert H., et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015, 16:447-456.
34. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
35. Kumar-Singh S., Weyler J., Martin M.J., et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J. Pathol. 1999, 189:72-78.
36. Linder C., Linder S., Munck-Wikland E., et al. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res. 1998, 18:2063-2068.
37. Ohta Y., Shridhar V., Bright R.K., et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer 1999, 81:54-61.
38. Kumar-Singh S., Vermeulen P.B., Weyler J., et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J. Pathol. 1997, 182:211-216.
39. Kindler H.L., Karrison T.G., Gandara D.R., et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J. Clin. Oncol. 2012, 30:2509-2515.
40. Dubey S., Janne P.A., Krug L., et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J. Thorac. Oncol. 2010, 5:1655-1661.
41. Laurie S.A., Gupta A., Chu Q., et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group. J. Thorac. Oncol. 2011, 6:1950-1954.
42. Jahan T., Gu L., Kratzke R., et al. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 2012, 76:393-396.
43. Campbell N.P., Kunnavakkam R., Leighl N., et al. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer 2012, 78:76-80.
44. Garland L.L., Chansky K., Wozniak A.J., et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J. Thorac. Oncol. 2011, 6:1938-1945.
45. Nowak A.K., Millward M.J., Creaney J., et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J. Thorac. Oncol. 2012, 7:1449-1456.
46. Buikhuisen W.A., Burgers J.A., Vincent A.D., et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2013, 14:543-551.
47. Gregorc V., Zucali P.A., Santoro A., et al. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J. Clin. Oncol. 2010, 28:2604-2611.
48. Nowak A.K., Brown C., Millward M.J., et al. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma. Lung Cancer 2013, 81:422-427.
49. Mathy A., Baas P., Dalesio O., et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005, 50:83-86.
50. Dudek A.Z., Pang H., Kratzke R.A., et al. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J. Thorac. Oncol. 2012, 7:755-759.
51. Destro A., Ceresoli G.L., Falleni M., et al. EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006, 51:207-215.
52. Garland L.L., Rankin C., Gandara D.R., et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J. Clin. Oncol. 2007, 25:2406-2413.
53. Jackman D.M., Kindler H.L., Yeap B.Y., et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008, 113:808-814.
54. Calabro L., Morra A., Fonsatti E., et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013, 14:1104-1111.
55. Calabro L., Morra A., Cutaia F.E., Fazio O., Danielli C.R., et al. A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. J. Clin. Oncol. 2014, 32. supplement (abstract # 7531).
56. Alley E.W., Molife R., Santoro A., Becey K., Yuan S., Cheng D., et al. Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-001. AACR Annual Meeting 2015, (abstract #CT103).
57. Chang K., Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:136-140.
58. Hassan R., Bera T., Pastan I. Mesothelin: a new target for immunotherapy. Clin. Cancer Res. 2004, 10:3937-3942.
59. Chowdhury P.S., Viner J.L., Beers R., et al. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:669-674.
60. Hassan R., Miller A.C., Sharon E., et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci. Transl. Med. 2013, 5. 208ra147.
61. Fennell D.A., McDowell C., Busacca S., Webb G., Moulton B., Cakana A., et al. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J. Thorac. Oncol. 2012, 7(9):1466-1470.